Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Update

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 166,389 shares, a decrease of 26.3% from the February 26th total of 225,823 shares. Currently, 3.4% of the shares of the company are sold short. Based on an average trading volume of 45,270 shares, the short-interest ratio is currently 3.7 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SBFM. Virtu Financial LLC acquired a new position in shares of Sunshine Biopharma during the fourth quarter valued at $29,000. Two Sigma Investments LP acquired a new stake in Sunshine Biopharma in the third quarter worth about $32,000. Finally, Citadel Advisors LLC lifted its holdings in Sunshine Biopharma by 23.1% in the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after purchasing an additional 14,656 shares during the period. Institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Price Performance

SBFM stock traded down $0.01 on Monday, reaching $1.01. The company’s stock had a trading volume of 38,695 shares, compared to its average volume of 36,263. Sunshine Biopharma has a 52 week low of $1.00 and a 52 week high of $3.90. The company has a market capitalization of $4.96 million, a P/E ratio of -0.99 and a beta of 1.50. The firm has a fifty day moving average of $1.16 and a two-hundred day moving average of $1.39.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sunshine Biopharma in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Sunshine Biopharma presently has an average rating of “Hold” and an average target price of $7.00.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.